Central European Advanced Therapy and Immunotherapy Centre

Personalised medicine as a key to treatment of rare diseases

Traditional treatments based on chemical drugs do not always work for rare diseases. They often focus on treating symptoms but fail to reverse the course of the disease itself. Personalised medicine using cell and gene therapies has the potential to reverse the negative prognosis of patients with unmet medical needs for whom there is no currently available conventional treatment.

No description


Our vision

The ultimate goal is to become a role model and flagship institution in the Central and Eastern European (CEE) region, providing excellent gene and somatic cell research to create personalised ATMP Fair Medicine for the treatment of life-threatening or chronically debilitating diseases that are currently considered incurable.

Our path to achieve the vision

CREATIC is Horizon Europe Teaming for Excellence project submitted in 9/2022. Masaryk University has established a partnership with Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig University and Copenhagen University to establish R&D centre of excellence focused on Advanced therapy medicinal products (ATMP). The strategic objectives of the project aim to use a grant of €15 million for 6 years in order to create an excellent facility for ATMP R&D focused on undiagnosed untreatable rare diseases, paediatric patients with high-risk tumours, and adult cancer patients suitable for ATMP treatment.

No description


Advanced European partners


Research programmes combining STM and SSH disciplines


launching the Centre of Excellence

Strategic goals

CREATIC has received funding from the European Union’s Horizon Europe Coordination and Support Action under the Grant agreement number 101059788.

The CREATIC Investment project submitted in the TEAMING-CZ I call (P JAC) is a complementary investment support for the CREATIC project submitted in the Teaming for Excellence (HE) call. The aim of the CREATIC Investment project is to provide complementary funding necessary for the further progress of the CREATIC (HE) project. 

No description

You are running an old browser version. We recommend updating your browser to its latest version.

More info